An Updated Systematic Review and Commentary Examining the Effectiveness of Radioactive Iodine Remnant Ablation in Well-Differentiated Thyroid Cancer

Endocrinology and Metabolism Clinics of North America

Volumn 37, Issue 2, 2008, Pages 457-480

  Sawka, Anna M ^a,b   Brierley, James D ^a,c   Tsang, Richard W ^a,c   Thabane, Lehana ^d,e   Rotstein, Lorne ^a,f   Gafni, Amiram ^d,g   Straus, Sharon ^h,i   Goldstein, David P ^h  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^f TORONTO GENERAL HOSPITAL   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN;

CANCER RECURRENCE; CLINICAL TRIAL; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; THYROID CANCER; THYROIDECTOMY;

CARCINOMA, PAPILLARY; CARCINOMA, PAPILLARY, FOLLICULAR; DISEASE PROGRESSION; HUMANS; IODINE RADIOISOTOPES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; RADIOTHERAPY, ADJUVANT; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 44049091056     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2008.02.007     Document Type: Review

References (47)

1. Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada, Public Health Agency of Canada. Canadian cancer statistics 2005. Available at: http://www.cancer.ca. Accessed August 2, 2005.
2. Hayat M.J., Howlader N., Reichman E., et al. Cancer statistics, trends, and multiple primary cancers from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12 (2007) 20-37
3. Davies L., and Welch H.G. Epidemiology of head and neck cancer in the United States. Otolaryngol Head Neck Surg 135 (2006) 451-457
4. Jonklaas J., Sarlis N.J., Litofsky D., et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16 (2006) 1229-1242
5. Eustatia-Rutten C.F.A., Corssmit E.P.M., Biermasz N.R., et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91 (2006) 313-319
6. Cooper D.S., Doherty G.M., Haugen B.R., et al., The American Thyroid Association Guidelines Task Force. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 109-142
7. National Cancer Institute. Thyroid cancer (PDQ): treatment. 2006. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/healthprofessio nal/allpages Accessed July 23, 2006.
8. Pacini F., Schlumberger M., Dralle H., et al., The European Thyroid Cancer Task Force. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154 (2006) 787-803
9. American Association of Clinical Endocrinologists, American College of Endocrinology, American Association of Endocrine Surgeons. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract 7 (2001) 202-220
10. British Thyroid Association, Royal College of Physicians. 2007 Guidelines for the management of thyroid cancer. 2nd edition. Available at: http://www.british-thyroid-association.org. Accessed October 20, 2007.
11. Sawka A.M., Thephamongkhol K., Brouwers M., et al. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89 (2004) 3668-3676
12. Vini L., Hyer S.L., Marshall J., et al. Long-term results in elderly patients with differentiated thyroid carcinoma. Cancer 97 (2003) 2736-2742
13. Brierley J., Tsang R., Panzarella T., et al. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single Canadian institution over 40 years. Clin Endocrinol (Oxf) 63 (2005) 418-427
14. Lang B.H., Lo C.Y., Chan W.F., et al. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol 14 (2007) 730-738
15. Pelizzo M.R., Boschin I.M., Toniato A., et al. Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin Nucl Med 32 (2007) 440-444
16. Lundgren C.I., Hall P., Dickman P.W., et al. Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer. Br J Surg 94 (2007) 571-577
17. Yildrim E. A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. J Am Coll Surg 200 (2005) 378-392
18. Pelizzo M.R., Boschin I.M., Toniato A., et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun 25 (2004) 547-552
19. Mazzaferri E.L., and Kloos R.T. Clinical Review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86 (2001) 1447-1463
20. Chow S.M., Law S.C., Mendenhall W.M., et al. Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 52 3 (2002) 784-795
21. Chow S.M., Law S.C., Au S.K., et al. Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute. Head Neck 24 (2002) 670-677
22. Balan K.K., Raouf A.H., and Critchley M. 1994 Outcome of 249 patients attending a nuclear medicine department with well differentiated thyroid cancer; a 23 year review. Br J Radiol 67 795 (1994) 283-291
23. Cunningham M.P., Duda R.B., Recant W., et al. Survival discriminants for differentiated thyroid cancer. Am J Surg 160 4 (1990) 344-347
24. Loh K.C., Greenspan F.S., Gee L., et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82 11 (1997) 3553-3562
25. Martins R.G., Caplan R.H., Lambert P.J., et al. Management of thyroid cancer of follicular cell origin: Gundersen/Lutheran Medical Center, 1969-1995. J Am Coll Surg 185 4 (1997) 388-397
26. Baudin E., Travagli J.P., Ropers J., et al. Microcarcinoma of the thyroid gland the Gustave-Roussy Institute experience. Cancer 83 (1998) 553-559
27. Samaan N.A., Schultz P.N., Hickey R.C., et al. The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75 (1992) 714-720
28. Herrera M.F., Lopez-Graniel C.M., Saldana J., et al. Papillary thyroid carcinoma in Mexican patients: clinical aspects and prognostic factors. World J Surg 20 1 (1996) 94-99
29. Simpson W.J., Panzarella T., Carruthers J.S., et al. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 14 6 (1988) 1063-1075
30. Carcangiu M.L., Zampi G., Pupi A., et al. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 55 4 (1985) 805-828
31. Hay I.D., McConahey W.M., and Goellner J.R. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 113 (2002) 241-260
32. DeGroot L.J., Kaplan E.L., McCormick M., et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71 2 (1990) 414-424
33. Gemsenjager E., Heitz P.U., Seifert B., et al. Differentiated thyroid carcinoma. Follow-up of 264 patients from one institution for up to 25 years. Swiss Med Wkly 131 11-12 (2001) 157-163
34. McHenry C.R., Rosen I.B., and Walfish P.G. Prospective management of nodal metastases in differentiated thyroid cancer. Am J Surg 162 4 (1991) 353-356
35. Morris D.M., Boyle P.J., Stidley C.A., et al. Localized well-differentiated thyroid carcinoma: survival analysis of prognostic factors and (131)I therapy. Ann Surg Oncol 5 4 (1998) 329-337
36. Tseng L.M., Lee C.H., Wang H.C., et al. The surgical treatment and prognostic factors of well-differentiated thyroid cancers in Chinese patients: a 20-year experience. Zhonghua Yi Xue Za Zhi (Taipei) 58 2 (1996) 121-131
37. Davis N.L., Gordon M., Germann E., et al. Efficacy of 131I ablation following thyroidectomy in patients with invasive follicular thyroid cancer. Am J Surg 163 5 (1992) 472-475
38. Saadi H., Kleidermacher P., and Esselstyn Jr. C. Conservative management of patients with intrathyroidal well-differentiated follicular thyroid carcinoma. Surgery 130 1 (2001) 30-35
39. Sanders L.E., and Silverman M. Follicular and Hürthle cell carcinoma: predicting outcome and directing therapy. Surgery 124 6 (1998) 967-974
40. Tsang R.W., Brierley J.D., Simpson W.J., et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 82 2 (1998) 375-388
41. Chow S.M., Law S.C., Au S.K., et al. Changes in presentation, management, and outcome in 1348 patients with differentiated thyroid carcinoma: experience in a single institute in Hong Kong, 1960-2000. Clin Oncol (R Coll Radiol) 15 (2003) 329-336
42. Chow S.M., Yau S., Kwan C.K., et al. Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer 13 (2006) 1159-1172
43. Chow S.M., Law S.C.K., Chan J.K.C., et al. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer 98 (2003) 31-40
44. Hay I.D. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 94 (2006) 692-700
45. Hackshaw A., Harmer C., Mallick U., et al. I-131 activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab 92 (2007) 28-38
46. Pilli T., Brianzoni E., Capoccettti F., et al. A comparison of 1859 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92 (2007) 3542-3546
47. Swaka A.M., Goldstein D.P., Thabane L., et al. Basis for physician recommendations for adjuvant radioactive iodine in early stage thyroid carcinoma: principal findings of the CAM-ThyrCa Survey. Endocr Prac 14 2 (2008) 175-184